Celyad Oncology SA
XBRU:CYAD

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
XBRU:CYAD
Watchlist
Price: 0.65 EUR -2.99% Market Closed
Market Cap: 14.7m EUR
Have any thoughts about
Celyad Oncology SA?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-1.2
Current
-0.4
Median
4.2
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-1.2
=
Enterprise Value
8.6m EUR
/
EBITDA
-7.2m EUR
All Countries
Close
Market Cap EV/EBITDA
BE
Celyad Oncology SA
XBRU:CYAD
14.7m EUR -1.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -218 147.8
US
Abbvie Inc
NYSE:ABBV
320.1B USD 15.6
US
Amgen Inc
NASDAQ:AMGN
150.5B USD 16.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD 25
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD 10
US
Epizyme Inc
F:EPE
94.1B EUR -517.9
AU
CSL Ltd
ASX:CSL
135.4B AUD 20.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.9B USD 16.3
US
Seagen Inc
F:SGT
39.3B EUR -59.2
NL
argenx SE
XBRU:ARGX
34.5B EUR -105.2
EBITDA Growth
BE
Celyad Oncology SA
XBRU:CYAD
Average EV/EBITDA: 17.4
Negative Multiple: -1.2
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 147.8 N/A
US
Abbvie Inc
NYSE:ABBV
15.6
29%
US
Amgen Inc
NASDAQ:AMGN
16.8
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25
43%
US
Gilead Sciences Inc
NASDAQ:GILD
10
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -517.9 N/A
AU
CSL Ltd
ASX:CSL
20.5
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.3
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.2 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A

See Also

Discover More